Drug-Induced Liver Injury Due To Losartan
Drug-induced liver injury (DILI) is a challenging diagnosis since a wide variety of medicines can cause adverse reactions. Losartan is an angiotensin II receptor antagonist (ARA-II) approved for the treatment of arterial hypertension. The most common adverse effects are fatigue, anaemia, weakness an...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SMC MEDIA SRL
2021-11-01
|
| Series: | European Journal of Case Reports in Internal Medicine |
| Subjects: | |
| Online Access: | https://www.ejcrim.com/index.php/EJCRIM/article/view/2856 |
| _version_ | 1819238986393059328 |
|---|---|
| author | Joana Diogo Rita Monteiro Carolina Coelho Angela Ghiletchi Rodrigo Leão Conceição Loureiro |
| author_facet | Joana Diogo Rita Monteiro Carolina Coelho Angela Ghiletchi Rodrigo Leão Conceição Loureiro |
| author_sort | Joana Diogo |
| collection | DOAJ |
| description | Drug-induced liver injury (DILI) is a challenging diagnosis since a wide variety of medicines can cause adverse reactions. Losartan is an angiotensin II receptor antagonist (ARA-II) approved for the treatment of arterial hypertension. The most common adverse effects are fatigue, anaemia, weakness and cough. An increase in transaminases has been reported with less frequency (<2% of cases). Although the mechanism is not fully understood, DILI onset is usually within 1–8 weeks of therapy, and hepatic enzymology usually normalizes 2–4 months after drug suspension. The authors present the case of a 66-year-old male patient with a medical history of arterial hypertension and a prior hospitalization (4 years previously) for drug-induced hepatitis, which, at the time, was attributed to a dietary supplement. Four years later, because of new onset of hypertension, losartan was reintroduced. After 3 weeks, the patient was admitted to the emergency department with complaints of acute abdominal pain associated with asthenia, nausea and increased abdominal volume that had first developed 8 days previously. After exclusion of other causes, DILI associated with losartan was assumed. This is a very rare adverse effect since only seven cases have been described in the literature. |
| first_indexed | 2024-12-23T13:44:56Z |
| format | Article |
| id | doaj.art-93c28cc6f36245fa92601c5faeae04ba |
| institution | Directory Open Access Journal |
| issn | 2284-2594 |
| language | English |
| last_indexed | 2024-12-23T13:44:56Z |
| publishDate | 2021-11-01 |
| publisher | SMC MEDIA SRL |
| record_format | Article |
| series | European Journal of Case Reports in Internal Medicine |
| spelling | doaj.art-93c28cc6f36245fa92601c5faeae04ba2022-12-21T17:44:45ZengSMC MEDIA SRLEuropean Journal of Case Reports in Internal Medicine2284-25942021-11-0110.12890/2021_0028562472Drug-Induced Liver Injury Due To LosartanJoana Diogo0Rita Monteiro1Carolina Coelho2Angela Ghiletchi3Rodrigo Leão4Conceição Loureiro5Centro Hospitalar Universitário Lisboa Central, Lisbon, PortugalCentro Hospitalar Universitário Lisboa Central, Lisbon, PortugalCentro Hospitalar Universitário Lisboa Central, Lisbon, PortugalCentro Hospitalar Universitário Lisboa Central, Lisbon, PortugalCentro Hospitalar Universitário Lisboa Central, Lisbon, PortugalCentro Hospitalar Universitário Lisboa Central, Lisbon, PortugalDrug-induced liver injury (DILI) is a challenging diagnosis since a wide variety of medicines can cause adverse reactions. Losartan is an angiotensin II receptor antagonist (ARA-II) approved for the treatment of arterial hypertension. The most common adverse effects are fatigue, anaemia, weakness and cough. An increase in transaminases has been reported with less frequency (<2% of cases). Although the mechanism is not fully understood, DILI onset is usually within 1–8 weeks of therapy, and hepatic enzymology usually normalizes 2–4 months after drug suspension. The authors present the case of a 66-year-old male patient with a medical history of arterial hypertension and a prior hospitalization (4 years previously) for drug-induced hepatitis, which, at the time, was attributed to a dietary supplement. Four years later, because of new onset of hypertension, losartan was reintroduced. After 3 weeks, the patient was admitted to the emergency department with complaints of acute abdominal pain associated with asthenia, nausea and increased abdominal volume that had first developed 8 days previously. After exclusion of other causes, DILI associated with losartan was assumed. This is a very rare adverse effect since only seven cases have been described in the literature.https://www.ejcrim.com/index.php/EJCRIM/article/view/2856losartandrug-induced liver injury |
| spellingShingle | Joana Diogo Rita Monteiro Carolina Coelho Angela Ghiletchi Rodrigo Leão Conceição Loureiro Drug-Induced Liver Injury Due To Losartan European Journal of Case Reports in Internal Medicine losartan drug-induced liver injury |
| title | Drug-Induced Liver Injury Due To Losartan |
| title_full | Drug-Induced Liver Injury Due To Losartan |
| title_fullStr | Drug-Induced Liver Injury Due To Losartan |
| title_full_unstemmed | Drug-Induced Liver Injury Due To Losartan |
| title_short | Drug-Induced Liver Injury Due To Losartan |
| title_sort | drug induced liver injury due to losartan |
| topic | losartan drug-induced liver injury |
| url | https://www.ejcrim.com/index.php/EJCRIM/article/view/2856 |
| work_keys_str_mv | AT joanadiogo druginducedliverinjuryduetolosartan AT ritamonteiro druginducedliverinjuryduetolosartan AT carolinacoelho druginducedliverinjuryduetolosartan AT angelaghiletchi druginducedliverinjuryduetolosartan AT rodrigoleao druginducedliverinjuryduetolosartan AT conceicaoloureiro druginducedliverinjuryduetolosartan |